[go: up one dir, main page]

CA3175102A1 - Inhibiteurs de recepteurs erbb utilises comme agents antitumoraux - Google Patents

Inhibiteurs de recepteurs erbb utilises comme agents antitumoraux

Info

Publication number
CA3175102A1
CA3175102A1 CA3175102A CA3175102A CA3175102A1 CA 3175102 A1 CA3175102 A1 CA 3175102A1 CA 3175102 A CA3175102 A CA 3175102A CA 3175102 A CA3175102 A CA 3175102A CA 3175102 A1 CA3175102 A1 CA 3175102A1
Authority
CA
Canada
Prior art keywords
pyrimidin
oxy
yloxy
difluoro
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3175102A
Other languages
English (en)
Inventor
Ding Zhou
Ziqiang CHENG
Zheng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
Suzhou Zanrong Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Zanrong Pharma Ltd filed Critical Suzhou Zanrong Pharma Ltd
Publication of CA3175102A1 publication Critical patent/CA3175102A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne de nouveaux composés utilisés comme inhibiteurs de récepteurs tyrosine kinases de type I, les compositions pharmaceutiques comprenant un ou plusieurs des composés et des sels de ceux-ci en tant que principe actif et l'utilisation des composés et des sels de ceux-ci dans le traitement de maladies hyperprolifératives, telles que le cancer et l'inflammation, chez des mammifères et en particulier chez l'homme.
CA3175102A 2020-03-13 2020-03-13 Inhibiteurs de recepteurs erbb utilises comme agents antitumoraux Pending CA3175102A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/079097 WO2021179274A1 (fr) 2020-03-13 2020-03-13 Inhibiteurs de récepteurs erbb utilisés comme agents antitumoraux

Publications (1)

Publication Number Publication Date
CA3175102A1 true CA3175102A1 (fr) 2021-09-16

Family

ID=77671069

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3175102A Pending CA3175102A1 (fr) 2020-03-13 2020-03-13 Inhibiteurs de recepteurs erbb utilises comme agents antitumoraux

Country Status (3)

Country Link
AU (2) AU2020435503B2 (fr)
CA (1) CA3175102A1 (fr)
WO (1) WO2021179274A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3213079A1 (fr) 2021-04-13 2022-10-20 Kristin Lynne ANDREWS Heterocycles amino-substitues pour le traitement de cancers avec des mutations egfr
TW202345816A (zh) * 2022-03-28 2023-12-01 大陸商江蘇恆瑞醫藥股份有限公司 含氮雜環類化合物、其製備方法及其在醫藥上的應用
TW202446386A (zh) * 2023-04-14 2024-12-01 大陸商迪哲（江蘇）醫藥股份有限公司 喹唑啉ＥｒｂＢ抑制劑的藥物形式
WO2025067396A1 (fr) * 2023-09-27 2025-04-03 江苏恒瑞医药股份有限公司 Sel pharmaceutiquement acceptable et forme cristalline d'un dérivé de quinazoline, et leur utilisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
DE60212487T2 (de) * 2001-04-13 2006-12-21 Pfizer Products Inc., Groton Bizyklisch substituierte 4-Aminopyridopyrimidinderivate
BRPI0410720A (pt) * 2003-05-27 2006-06-20 Pfizer Prod Inc quinazolinas e pirido[3,4-d]pirimidinas como inibidores do receptor de tirosina cinase
CA2608362A1 (fr) * 2005-05-18 2006-11-23 Wyeth Inhibiteurs de 4, 6-diamino-[1,7] naphthyridine-3-carbonitrile de la tpl2 kinase et procedes de fabrication et d'utilisation de ceux-ci
DK1971601T3 (da) * 2005-11-15 2010-02-08 Array Biopharma Inc N4-phenyl-quinazolin-4-aminderivater og beslægtede forbindelser som ERBB Type 1-receptortyrosinkinase-inhibitorer til behandling af hyperproliferative sygdomme

Also Published As

Publication number Publication date
AU2025203211A1 (en) 2025-05-29
AU2020435503B2 (en) 2025-02-20
AU2020435503A1 (en) 2022-10-20
WO2021179274A1 (fr) 2021-09-16

Similar Documents

Publication Publication Date Title
US20230293533A1 (en) Quinazoline derivatives as antitumor agents
KR102746913B1 (ko) Sos1 억제제로서의 신규 벤질아미노 치환 피리도피리미디논 및 유도체
AU2017286380B2 (en) Azabenzimidazole derivatives as PI3K beta inhibitors
KR20240128852A (ko) 암 치료를 위한 고리형 2-아미노-3-시아노 티오펜 및 유도체
AU2017289315B2 (en) Heteroaromatic derivatives as NIK inhibitors
TW201837045A (zh) 胺基-三唑并吡啶化合物及其在治療癌症中之用途
AU2025203211A1 (en) ErbB RECEPTOR INHIBITORS AS ANTI-TUMOR AGENTS
BRPI0618668A2 (pt) composto, composição, método pra o tratamento de uma doença hiperproliferativa em um mamìfero, uso de um composto e método para a preparação de um composto
JP7706585B2 (ja) 毛細血管拡張性運動失調症変異（ＡＴＭ）キナーゼの選択的調節物質としての１－イソプロピル－３－メチル－８－（ピリジン－３－イル）－１，３－ジヒドロ－２Ｈ－イミダゾ［４，５－ｃ］シンノリン－２－オンおよびその使用
JP2019518032A (ja) Ｐｉ３ｋ ｂｅｔａ阻害薬としての二環式ピリジン、ピラジンおよびピリミジン誘導体
KR20250171398A (ko) 항종양제로서의 퀴나졸린 유도체
US20250235456A1 (en) Methods of use for aza-quinazoline compounds
CN117794940A (zh) 用作抗癌药剂的稠合杂芳基化合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240208